Baerveldt shunt lowers IOP

Article

Baerveldt shunts effectively lower IOP in eyes with anterior uveal melanoma (AUM) undergoing anterior segment irradiation.

Baerveldt shunts effectively lower IOP in eyes with anterior uveal melanoma (AUM) undergoing anterior segment irradiation.

An investigation, led by Dr Eamon Sharkawi, Hôpital Ophtalmique Jules-Gonin, Université de Lausanne, Switzerland, including 31 eyes with uncontrolled IOP. Each patient underwent anterior segment proton beam radiotherapy (PBRT) and Baerveldt shunt implantation.

Postoperative assessments were conducted on day 1, weeks 1, 3, 6, 9 and months 3, 6, 9 and 12 annually thereafter. IOP that was 21 mm Hg or less was defined as a surgical success, as well as 20% reduction from baseline.

Mean preoperative IOP was recorded at 3.10 mm Hg and mean IOP at the last visit was 15.0 mm Hg. The surgical success rate was 86% after using glaucoma medications. Of the eyes studied, four had minor postoperative complications but there were no local tumour recurrences, systemic metastases or no enucleations caused by ocular hypertension.

The abstract can be found in the British Journal of Ophthalmology.

Recent Videos
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
© 2025 MJH Life Sciences

All rights reserved.